Pregabalin, Celecoxib, Total Knee Arthroplasty and Intrathecal Morphine
Launched by CHULALONGKORN UNIVERSITY · Apr 27, 2011
Trial Information
Current as of May 25, 2025
Completed
Keywords
ClinConnect Summary
A single-dose spinal anesthesia combining with morphine for total knee arthroplasty (TKA) is a simple, economical anesthetic technique commonly used in our hospital. Still some patients could not get effective postoperative pain control. Pregabalin, an anticonvulsant, has been shown to reduce acute pain after molar extraction, laparoscopic cholecystectomy, and reduce postoperative morphine requirement after total hip arthroplasty, and celecoxib, a selective cyclo-oxygenase (COX) - 2 inhibitor, with perioperative prescription is successfully reduces pain score and opioid consumption after TK...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients between 50-75 years of age
- • Patients with an American Society of Anesthesiologists physical status of I to III
- • Patients scheduled for primary TKA with a diagnosis of osteoarthritis under spinal anesthesia
- • Exclusion Criteria:.
- • Patients had a known allergy to any of the medications being used
- • a history of drug or alcohol abuse
- • a history of taking chronic pain medications (ie, show-release preparations of opioids, given that morphine consumption was the primary outcome)
- • a history of taking pregabalin or gabapentin / non-steroidal anti-inflammatory drugs / COX-2 inhibitors
- • a psychiatric disorder
- • a history of impaired renal function (Cr \> 1.5 mg/dl), peptic ulcer, asthma, thrombotic cerebrocardiovascular diseases, uncontrolled hypertension
- • a history of contraindication for spinal anesthesia
- • a history of bleeding tendency
- • pregnancy
- • unable or unwilling to use patient - controlled analgesic (PCA)
About Chulalongkorn University
Chulalongkorn University, one of Thailand's premier academic institutions, is dedicated to advancing medical research and enhancing healthcare outcomes through innovative clinical trials. With a strong emphasis on collaboration and interdisciplinary approaches, the university leverages its extensive resources and expertise in various medical fields to conduct rigorous scientific investigations. Chulalongkorn University aims to contribute to global health advancements by fostering a culture of excellence in research, education, and community service, ultimately improving patient care and public health standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkok, , Thailand
Patients applied
Trial Officials
Supranee Niruthisard, BSc, MD
Principal Investigator
King Chulalongkorn Memorial Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials